PHAGOCYTIC KILLING OF ENCAPSULATED AND MICROENCAPSULATED STAPHYLOCOCCUS-AUREUS BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES

被引:47
作者
XU, SL
ARBEIT, RD
LEE, JC
机构
[1] HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115
[2] VET AFFAIRS MED CTR,MED SERV,BOSTON,MA 02130
关键词
D O I
10.1128/IAI.60.4.1358-1362.1992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Phagocytosis by human polymorphonuclear leukocytes (PMNs) is an important host defense against infections caused by Staphylococcus aureus. Using an in vitro assay, we compared the opsonic requirements for phagocytic killing of prototype strains of encapsulated (type 1) and microencapsulated (type 5 and type 8) S. aureus by human PMNs. More than 85% of broth-grown, logarithmic-phase type 5 and 8 S. aureus organisms were killed by PMNs incubated with fresh normal human, rabbit, or guinea pig serum with complement activity. Under similar conditions, the highly encapsulated type 1 strain was not killed. Both encapsulated and microencapsulated strains were opsonized for phagocytosis by heat-inactivated serum raised in rabbits to killed bacteria. Opsonization by homologous serum was required for phagocytosis of the type 1 strain. In contrast, microencapsulated type 5 and 8 S. aureus organisms were killed by heat-inactivated rabbit serum raised to type 5, type 8, or nonencapsulated isolates; this result suggested that antibodies to the capsule or to cell wall components other than the capsule could opsonize these organisms for phagocytosis. The specificity of the assay was confirmed with capsule type 5-specific monoclonal antibodies, which were opsonic only for the type 5 S. aureus isolate. These studies indicate that, unlike the highly encapsulated type 1 strain, broth-grown microencapsulated S. aureus strains do not resist opsonophagocytic killing in vitro by normal serum.
引用
收藏
页码:1358 / 1362
页数:5
相关论文
共 30 条
[1]   STAPHYLOCOCCUS-AUREUS CAPSULAR TYPES AND ANTIBODY-RESPONSE TO LUNG INFECTION IN PATIENTS WITH CYSTIC-FIBROSIS [J].
ALBUS, A ;
FOURNIER, JM ;
WOLZ, C ;
BOUTONNIER, A ;
RANKE, M ;
HOIBY, N ;
HOCHKEPPEL, H ;
DORING, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (12) :2505-2509
[2]   VIRULENCE OF STAPHYLOCOCCUS-AUREUS MUTANTS ALTERED IN TYPE-5 CAPSULE PRODUCTION [J].
ALBUS, A ;
ARBEIT, RD ;
LEE, JC .
INFECTION AND IMMUNITY, 1991, 59 (03) :1008-1014
[3]   PREDOMINANCE OF 2 NEWLY DESCRIBED CAPSULAR POLYSACCHARIDE TYPES AMONG CLINICAL ISOLATES OF STAPHYLOCOCCUS-AUREUS [J].
ARBEIT, RD ;
KARAKAWA, WW ;
VANN, WF ;
ROBBINS, JB .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1984, 2 (02) :85-91
[4]  
BADDOUR LM, IN PRESS J INFECT DI
[5]  
CHRISTENSSON B, 1990, J INFECT DIS, V163, P530
[6]  
COHN ZA, 1962, YALE J BIOL MED, V35, P12
[7]   SYNTHESIS AND IMMUNOLOGICAL PROPERTIES IN MICE OF VACCINES COMPOSED OF STAPHYLOCOCCUS-AUREUS TYPE-5 AND TYPE-8 CAPSULAR POLYSACCHARIDES CONJUGATED TO PSEUDOMONAS-AERUGINOSA EXOTOXIN-A [J].
FATTOM, A ;
SCHNEERSON, R ;
SZU, SC ;
VANN, WF ;
SHILOACH, J ;
KARAKAWA, WW ;
ROBBINS, JB .
INFECTION AND IMMUNITY, 1990, 58 (07) :2367-2374
[8]  
GANSTROM M, 1983, J CLIN MICROBIOL, V17, P640
[9]   ANTIBODY-RESPONSES TO PROTEIN A IN PATIENTS WITH STAPHYLOCOCCUS-AUREUS BACTEREMIA AND ENDOCARDITIS [J].
GREENBERG, DP ;
BAYER, AS ;
TURNER, D ;
WARD, JI .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) :458-462
[10]   INFLUENCE OF STAPHYLOCOCCUS-AUREUS ANTIBODY ON EXPERIMENTAL ENDOCARDITIS IN RABBITS [J].
GREENBERG, DP ;
WARD, JI ;
BAYER, AS .
INFECTION AND IMMUNITY, 1987, 55 (12) :3030-3034